

Meet-the-Expert Sessions

**SATURDAY, DECEMBER 4, AND
SUNDAY, DECEMBER 5
11:15 A.M. – 12:15 P.M.**

The Meet-the-Expert sessions are designed to provide an opportunity for a small number of attendees to meet with an expert in a setting that fosters interaction. This year, ASH has invited experts from all over the world to facilitate informal discussions allowing participants to present their questions and gain new perspectives. A boxed lunch will be provided.

Ticket Prices (per session)

Member: \$25

Non-Member in Training: \$25

Non-Member: \$40

The Meet-the-Expert Sessions are restricted to medical professionals only; no businesspersons or media will be admitted. Tickets are limited and only available on site on a first-come, first-served basis. Only one ticket per person is allowed. These tickets can be purchased at the Meet-the-Expert counter in the registration area of the Orange County Convention Center beginning Thursday, December 2, during registration hours until all tickets are sold. The room assignment will be indicated on the ticket. Please check your ticket carefully to ensure proper date, time, location, and session choice.

Attention Trainees!

A number of tickets for the Meet-the-Expert Sessions will be reserved especially for trainees. Proof of status as an Associate member or non-member in training will be required to purchase a ticket. Please show your name badge to the staff at the Meet-the-Expert ticket counter.

Schedule Subject to Change

Please note that the Meet-the-Expert Session schedule included here is not final. Please check the ASH website (www.hematology.org) in late September to view the schedule.

Saturday

John W. Adamson, MD, University of California - San Diego, San Diego, CA
Erythropoietin Therapy: Minimizing Risk and Maximizing Benefit

Stephen M. Ansell, MD, PhD, Mayo Clinic, Rochester, MN
Hodgkin Lymphoma

Juliet Barker, MBBS, Memorial Sloan-Kettering Cancer Center, New York, NY
Cord Blood Transplantation

Marc Carrier, MD, MSc, University of Ottawa, Ottawa, ON, Canada
Venous Thromboembolism and Cancer: Prevention and Treatment

Christine Chen, MD, Princess Margaret Hospital, Toronto, ON, Canada
IMiDS and Chronic Lymphocytic Leukemia

Jorge Di Paola, MD, University of Colorado - Denver, School of Medicine, Aurora, CO
Von Willebrand Disease

Cynthia E. Dunbar, MD, Editor-in-Chief, *Blood*, Washington, DC
Publishing Laboratory and Clinical Studies

Christopher Flowers, MD, MSc, Winship Cancer Institute, Atlanta, GA
Survivorship in Lymphoma

Andre Goy, MD, John Theurer Cancer Center, Hackensack, NJ
Mantle Cell Lymphoma

Andreas Greinacher, MD, Institute for Immunology and Transfusion, Greifswald, Germany
Thrombocytopenia: From Hemolytic Uremia Syndrome to Heparin-Induced Thrombocytopenia

Ronald Hoffman, MD, Mount Sinai School of Medicine, New York, NY
Myeloproliferative Diseases

Jonathan D. Licht, MD, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
Entering miRNA Research: Principles, Technologies, Promise, and Pitfalls

Francesco Lo-Coco, MD, University Tor Vergata, Rome, Italy
Using Molecular Diagnostics to Guide Management of Acute Leukemia

Guido Marcucci, MD, The Ohio State University, Columbus, OH
Prognostic Markers in Acute Myelocytic Leukemia

Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN
NK Cells and Bone Marrow Transplant

Margaret V. Ragni, MD, University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA
Liver Disease in Hemophilia

Alan G. Rosmarin, MD, UMass Memorial Medical School, Worcester, MA
Developmental Transcription Factors Gone Wild: Dissecting the Origins of Leukemia

Rita Selby, MBBS, MSc, Sunnybrook HSC and University Health Network, Toronto, ON, Canada
The Laboratory and Venous Thromboembolism

Ayalew Tefferi, MD, Mayo Clinic Graduate School of Medicine, Rochester, MN
Polycythemia Rubra Vera

John Tisdale, MD, Maternal and Child Health Bureau, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Sickle Cell Disease and Transplant

Donna Weber, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Future Therapies for Myeloma

Daniel J. Weisdorf, MD, University of Minnesota, Minneapolis, MN
Acute Graft-Versus-Host Disease

Jeffrey I. Weitz, MD, Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada
Emerging Role for New Oral Anticoagulants

David A. Williams, MD, Children's Hospital Boston, Boston, MA
What Future for Gene Therapy?

Sunday

P. Leif Bergsagel, MD, Mayo Clinic, Scottsdale, AZ
Signaling in Multiple Myeloma: From Prognosis to Therapy

Martin Carroll, MD, University of Pennsylvania, Philadelphia, PA
Acute Myeloid Leukemia

Joel Anne Chasis, MD, Lawrence Berkeley Laboratory, Berkeley, CA
Erythropoiesis Island Niche and Anemias

Linzhao Cheng, PhD, The Johns Hopkins University School of Medicine, Baltimore, MD
How to Get Started With iPS Cells in Your Lab

John F. Di Persio, MD, PhD, Washington University School of Medicine, St. Louis, MO
Strategies for Stem Cell Mobilization

Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN
Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome and Amyloidosis

Benjamin L. Ebert, MD, DPhil, Brigham and Women's Hospital, Boston, MA
5q- Syndrome

Elizabeth A. Eklund, MD, Northwestern University Feinberg School of Medicine and Jesse Brown VA Medical Center, Chicago, IL
DNA-Repair Defects in Acute Leukemias: Can They Be Exploited?

A. Victor Hoffbrand, DM, DSc, Royal Free Hospital, London, England
Megaloblastic Anemias

Shaji K. Kumar, MD, Mayo Clinic, Rochester, MN
Initial Therapy of Myeloma

Paul Monagle, MBBS, MD, MSc, The University of Melbourne, Parkville, Victoria, Australia
Pediatric Anticoagulation

Elaine A. Muchmore, MD, University of California - San Diego, San Diego, CA
Fellowship Training and Hematology

Steven Z. Pavletic, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD
Chronic Graft-Versus-Host Disease

Azra Raza, MD, St. Vincent's Comprehensive Cancer Center, New York, NY
Myelodysplastic Syndromes

Miguel A. Sanz, MD, PhD, University Hospital La Fe, Valencia, Spain
Acute Promyelocytic Leukemia

Seema Singhal, MD, Northwestern University Feinberg School of Medicine, Chicago, IL
Stem Cell Transplant and Myeloma

Donald Small, MD, PhD, The Johns Hopkins University School of Medicine, Baltimore, MD
Flt3 Inhibitors: Ready for Prime Time?

Louis M. Staudt, MD, PhD, National Cancer Institute, National Institutes of Health, Bethesda, MD
Aggressive Lymphomas

Kimberly Stegmaier, MD, Dana-Farber Cancer Institute and The Broad Institute of Harvard University and Massachusetts Institute of Technology, Boston, MA
Identifying and Therapeutically Exploiting Molecular Vulnerabilities in Leukemia: New Drug Development

Rainer F. Storb, MD, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
Issues in Stem Cell Transplantation

Deborah A. Thomas, MD, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Acute Lymphoblastic Leukemia

Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Waldenström Macroglobulinemia

Amy J. Wagers, PhD, Joslin Diabetes Center, Boston, MA
Stem Cell Aging

Michael E. Williams, MD, University of Virginia, Charlottesville, VA
Immunotherapy for Lymphoma

Neal S. Young, MD, National Institutes of Health, Bethesda, MD
Aplastic Anemia

